The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The author says the action creates mistrust of the committee’s vaccine recommendations and further increases patients’ and ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Wall Street notched another record close on Thursday, as market participants snapped up equities and dumped bonds after nonfarm payrolls jumped more than expected in June. The S&P 500 Health Care ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

For decades, one of the world’s most contagious diseases was considered eradicated in the U.S. But today, measles is roaring ...